Literature DB >> 15622326

CD4 cell decline with didanosine and tenofovir and failure of triple nucleoside/nucleotide regimens may be related.

Thomas N Kakuda, Peter L Anderson, Stephen L Becker.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15622326

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  5 in total

1.  Intracellular nucleotide levels during coadministration of tenofovir disoproxil fumarate and didanosine in HIV-1-infected patients.

Authors:  Trevor Hawkins; Wenoah Veikley; Lucie Durand-Gasselin; Darius Babusis; Y Sunila Reddy; John F Flaherty; Adrian S Ray
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

2.  Analysis of the Endogenous Deoxynucleoside Triphosphate Pool in HIV-Positive and -Negative Individuals Receiving Tenofovir-Emtricitabine.

Authors:  Xinhui Chen; Jose R Castillo-Mancilla; Sharon M Seifert; Kevin B McAllister; Jia-Hua Zheng; Lane R Bushman; Samantha MaWhinney; Peter L Anderson
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

3.  Model for intracellular Lamivudine metabolism in peripheral blood mononuclear cells ex vivo and in human immunodeficiency virus type 1-infected adolescents.

Authors:  Zexun Zhou; John H Rodman; Patricia M Flynn; Brian L Robbins; Carrie K Wilcox; David Z D'Argenio
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

Review 4.  Once-daily therapies for the treatment of HIV infection.

Authors:  Karen T Tashima; Jennifer Adelson Mitty
Journal:  Curr HIV/AIDS Rep       Date:  2006-07       Impact factor: 5.071

5.  Reduced immune activation during tenofovir-emtricitabine therapy in HIV-negative individuals.

Authors:  Jose R Castillo-Mancilla; Amie Meditz; Cara Wilson; Jia-Hua Zheng; Brent E Palmer; Eric J Lee; Edward M Gardner; Sharon Seifert; Becky Kerr; Lane R Bushman; Samantha MaWhinney; Peter L Anderson
Journal:  J Acquir Immune Defic Syndr       Date:  2015-04-15       Impact factor: 3.731

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.